07 September 2017
Local manufacturer Pharmstandard will make the finished dosage form of Roche’s monoclonal antibody Gazyva (obinutuzumab) at its site in Ufa. The policy has driven most multinationals to sign contracts with domestic drugmakers and invest in local joint ventures. Pfizer broke ground on a facility with NovaMedica in Kaluga in May, GSK formed a JV with Binnopharm in 2011, while AstraZeneca , Novartis and Novo Nordisk have all invested in Russian production facilities.
17 August 2017
Insights From: Emmanuel S. Antonarakis, MBBCh, Johns Hopkins Medicine; Andrew J. Armstrong, MD, MSc, Duke Cancer Center; Howard I. Scher, MD, Memorial Sloan Kettering Cancer Center share their views on the Epic Sciences AR-V7 test in development for prostate cancer.
29 August 2017
Maxim Gorbachev, Managing Partner of RMI Partners: "New technologies make dramatic changes to business. They even reached financing of venture capital companies. Use of crypto-currency has resulted into development of the new mechanism of crowdfunding – Initial Coin Offering (ICO) which is in a way similar to public share placement (IPO). Venture projects utilize blockchain technologies to create and sell digital tokens, thus raising funds from investors. When initially ICO was used as mechanism to develop new crypto-currency instruments such as Ethereum, nowadays ICO serve as a democratic mechanism of fund raising for any project. And this instrument cannot be ignored due to amounts of funds raised this way."
11 August 2017
Rustam Iksanov, who used to hold one of the managerial positions in Valenta Pharma, has been appointed as R&D Vice President of pharmaceutical company NovaMedica.
29 May 2017
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the appointment of Alexander Kuzin to the post of General Director (CEO). This decision has taken unanimously by the Board of Directors of NovaMedica on May 26, 2017.
30 May 2017
Russian pharmaceutical company NovaMedica, a portfolio company of RUSNANO, announces the start of construction of a plant for the production of sterile injectable drugs as part of its long-term strategy to localize innovative medicines and technologies of their development and production in Russia. The plant will be built in the industrial park “Vorsino” in the Kaluga region.
26 September 2017
Iranian biotech medicines exported to Russia have taken over the country’s market 100% and have replaced their American versions, according to National Talents Foundation.
26 September 2017
LabCentral and Pfizer announced plans to open LabCentral 610, a new LabCentral offering located at Pfizer’s Kendall Square Worldwide Research and Development campus, Cambridge, Massachusetts, U.S. The facility is slated to open in December and will house up to six early- to mid-stage companies.
25 September 2017
The research activities of Genomic and Regenerative Medicine Center established at the School of Biomedicine in the Far Eastern Federal University (FEFU) will be based on unique natural resources of the Russian Far East. The scientists will study the biodiversity of the region, including marine organisms, create a bank of biomolecules for new drugs, and introduce innovative diagnostic and treatment methods into routine medical practice.
25 September 2017
During the second BIOTECHMED conference held in Gelendzhik, the representatives of Nacimbio, a company which is part of Rostec Corporation, participated in panel discussions on preventive vaccination and expansion of the National Immunization Calendar.